Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
0.975
-0.045 (-4.41%)
At close: Jan 31, 2025, 4:00 PM
0.980
+0.005 (0.51%)
After-hours: Jan 31, 2025, 5:12 PM EST
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
77
Market Cap
87.83M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
IMUX News
- 25 days ago - Immunic Highlights 2024 Accomplishments and Upcoming Milestones - PRNewsWire
- 2 months ago - Immunic, Inc. to Participate in Investor Conference in December - PRNewsWire
- 2 months ago - Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PRNewsWire
- 3 months ago - Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - PRNewsWire
- 3 months ago - Immunic to Participate in Industry, Scientific and Investor Conferences in November - PRNewsWire
- 3 months ago - Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - PRNewsWire